The Best Stocks to Invest $40 in to Start the New Year Off Right

Group 1: Pfizer - Pfizer's stock is currently priced at $26 per share, reflecting a challenging performance over the past three years, but the company is taking steps to improve its financial results and address patent cliffs [2] - The company is conducting clinical trials for a promising cancer drug, PF-4404, which is expected to secure approvals across various cancer types [2][3] - Pfizer has also acquired a promising mid-stage asset in weight management, MET-097i, indicating a strong pipeline in oncology, immunology, and vaccines [3][5] - The market capitalization of Pfizer is $146 billion, with a gross margin of 69.12% and a dividend yield of 8.38%, suggesting financial stability [5] - Pfizer has signed a deal with the White House to be exempt from tariffs on imports for three years, which will help mitigate financial threats [5] - Although a rebound may not occur this year, the stock is considered attractive for long-term investors, with potential for superior returns over the next decade [6] Group 2: Viking Therapeutics - Viking Therapeutics is currently priced at $34 per share and is classified as a riskier investment due to its status as a clinical-stage biotech with no market products [7] - The leading candidate, VK2735, is a promising weight-loss medicine undergoing phase 3 studies, with an oral version also in mid-stage trials [7][10] - The company is implementing a multi-pronged approach to differentiate its products, including a maintenance study for patients who have lost weight with VK2735 [8] - Viking's market capitalization stands at $3.6 billion, with a 52-week price range of $18.92 to $43.15, indicating volatility [9][10] - The success of Viking's clinical progress in the next two years could significantly increase its stock value, although there are risks associated with clinical and regulatory setbacks [10]